AVITA Medical, Inc. (RCEL) shareholders
Close on Nov 17, 2026Market cap $487.72MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RCEL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,333,914 | – | $5.51M | −1,238 | 0.00% |
| BlackRock, Inc. | 564,952 | – | $2.33M | −568,174 | 0.00% |
| Geode Capital Management, LLC | 339,822 | – | $1.40M | −203,152 | 0.00% |
| Marshall Wace, Llp | 338,387 | – | $1.40M | +285,825 | 0.00% |
| Aqr Capital Management LLC | 321,013 | – | $1.33M | +226,652 | 0.00% |
| Morgan Stanley | 200,462 | – | $827.91K | +42,841 | 0.00% |
| Vanguard Fiduciary Trust Co | 182,402 | – | $753.32K | −11,034 | 0.00% |
| NewEdge Advisors, LLC | 148,931 | – | $615.09K | +62,046 | 0.00% |
| Macquarie Group Ltd | 144,164 | – | $595.40K | +132,262 | 0.00% |
| State Street Corp | 128,977 | – | $532.68K | −300,045 | 0.00% |
| Quantinno Capital Management LP | 105,248 | – | $434.67K | +82,765 | 0.00% |
| Divisadero Street Capital Management, LP | 100,000 | – | $413.00K | – | 0.01% |
| UBS Group AG | 84,033 | – | $347.06K | +21,579 | 0.00% |
| Goldman Sachs Group Inc | 76,737 | – | $316.92K | −23,108 | 0.00% |
| Northern Trust Corp | 68,973 | – | $284.86K | −114,208 | 0.00% |
| Qube Research & Technologies Ltd | 63,784 | – | $263.43K | New | 0.00% |
| Arrowstreet Capital, Limited Partnership | 60,746 | – | $250.88K | New | 0.00% |
| XTX Topco Ltd | 57,161 | – | $236.08K | New | 0.00% |
| Bnp Paribas Arbitrage, Snc | 53,958 | – | $222.85K | +50,791 | 0.00% |
| Bank Of America Corp /De/ | 51,667 | – | $213.38K | −10,461 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | 5M | 20 / 25 | 21 / 24 | 1M | 2M |
| Q1 2026 | 79 | 6M | 26 / 29 | 11 / 13 | 3M | 0M |
| Q4 2025 | 67 | 5M | 8 / 14 | 29 / 17 | 0M | 1M |
| Q3 2025 | 76 | 5M | 16 / 13 | 35 / 20 | 1M | 3M |
| Q2 2025 | 80 | 8M | 19 / 23 | 23 / 13 | 1M | 1M |
| Q1 2025 | 74 | 7M | 14 / 25 | 18 / 12 | 1M | 1M |
| Q4 2024 | 73 | 6M | 14 / 28 | 14 / 8 | 0M | 0M |
| Q3 2024 | 67 | 6M | 12 / 24 | 16 / 12 | 2M | 1M |
| Q2 2024 | 68 | 6M | 13 / 25 | 20 / 25 | 1M | 2M |
| Q1 2024 | 82 | 7M | 12 / 24 | 28 / 14 | 1M | 1M |
| Q4 2023 | 84 | 7M | 22 / 18 | 26 / 18 | 1M | 2M |
| Q3 2023 | 80 | 8M | 10 / 22 | 32 / 10 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
83 funds held RCEL in Q1 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Cary Guy Vance | President and CEO, Director | 40,771 | Jun 1, 2026 |
| James Corbett | CEO, Director | 11,580 | Jun 5, 2025 |
| David D. O'Toole | CFO | 152,927 | Aug 24, 2026 |
| Nicole Kelsey | Chief Legal Officer | 98,390 | Feb 19, 2026 |
| Joseph Fralin Woody | Director | 107,961 | Jun 10, 2026 |
| Robert McNamara | Director | 108,985 | Jun 4, 2026 |
| Suzanne Crowe | Director | 69,148 | Jun 4, 2026 |
| Jeremy Curnock Cook | Director | 62,050 | Jun 4, 2026 |
| Michael E. Tarnoff | Director | 48,464 | Jun 4, 2026 |
| Jan Stern Reed | Director | 73,225 | Jun 4, 2026 |
| Lou Panaccio | Director | 62,400 | Jun 5, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David D. O'Toole CFO | Jun 12, 2026 | Buy | +2,000 | $3.97 | $7.94K | 152,927 |
| David D. O'Toole CFO | Jun 12, 2026 | Award | +2,000 | $3.97 | $7.94K | 152,927 |
| Joseph Fralin Woody Director | Jun 9, 2026 | Buy | +5,200 | $4.00 | $20.80K | 107,961 |
| Joseph Fralin Woody Director | Jun 9, 2026 | Buy | +5,000 | $4.20 | $21.00K | 97,761 |
| Joseph Fralin Woody Director | Jun 9, 2026 | Buy | +5,000 | $4.18 | $20.90K | 102,761 |
| Joseph Fralin Woody Director | Jun 3, 2026 | Buy | +5,000 | $4.10 | $20.50K | 87,761 |
| Joseph Fralin Woody Director | Jun 3, 2026 | Buy | +5,000 | $4.09 | $20.45K | 92,761 |
| Joseph Fralin Woody Director | Jun 2, 2026 | Buy | +5,000 | $4.18 | $20.90K | 15,000 |
| Joseph Fralin Woody Director | Jun 2, 2026 | Buy | +5,000 | $4.21 | $21.05K | 20,000 |
| Joseph Fralin Woody Director | Jun 1, 2026 | Buy | +5,000 | $4.34 | $21.70K | 5,000 |
| Joseph Fralin Woody Director | Jun 1, 2026 | Buy | +5,000 | $4.26 | $21.30K | 10,000 |
| Cary Guy Vance President and CEO, Director | May 29, 2026 | Award | +5,000 | $3.05 | $15.25K | 40,771 |
| David D. O'Toole CFO | May 29, 2026 | Award | +5,000 | $3.05 | $15.25K | 150,927 |
| David D. O'Toole CFO | May 20, 2026 | Buy | +2,000 | $4.26 | $8.52K | 145,927 |
| David D. O'Toole CFO | May 19, 2026 | Buy | +2,000 | $4.24 | $8.48K | 143,927 |
| David D. O'Toole CFO | Mar 11, 2026 | Buy | +1,800 | $4.78 | $8.60K | 141,927 |
| David D. O'Toole CFO | Feb 19, 2026 | Buy | +3,000 | $4.15 | $12.45K | 140,127 |
| David D. O'Toole CFO | Feb 18, 2026 | Award | +105,470 | – | – | 137,127 |
| Nicole Kelsey Chief Legal Officer | Feb 18, 2026 | Award | +98,390 | – | – | 98,390 |
| Jeremy Curnock Cook Director | Jan 20, 2026 | Award | +22,214 | – | – | 62,050 |
| Joseph Fralin Woody Director | Jan 20, 2026 | Award | +22,214 | – | – | 82,761 |
| Robert McNamara Director | Jan 20, 2026 | Award | +22,214 | – | – | 108,985 |
| Suzanne Crowe Director | Jan 20, 2026 | Award | +22,214 | – | – | 69,148 |
| Michael E. Tarnoff Director | Jan 20, 2026 | Award | +22,214 | – | – | 48,464 |
| Jan Stern Reed Director | Jan 20, 2026 | Award | +22,214 | – | – | 73,225 |
| Joseph Fralin Woody Director | Jan 5, 2026 | Award | +40,547 | – | – | 60,547 |
| Robert McNamara Director | Aug 28, 2025 | Buy | +10,000 | $4.50 | $45.00K | 86,771 |
| David D. O'Toole CFO | Aug 26, 2025 | Buy | +2,000 | $4.52 | $9.04K | 31,657 |
| Robert McNamara Director | Aug 19, 2025 | Buy | +10,000 | $5.00 | $50.00K | 76,771 |
| David D. O'Toole CFO | Aug 12, 2025 | Buy | +2,000 | $4.81 | $9.62K | 29,657 |
| Michael E. Tarnoff Director | Aug 6, 2025 | Award | +26,250 | – | – | 26,250 |
| David D. O'Toole CFO | May 30, 2025 | Award | +1,923 | $4.78 | $9.19K | 27,657 |
| Robert McNamara Director | Mar 6, 2025 | Buy | +11,000 | $8.30 | $91.30K | 56,749 |
| Robert McNamara Director | Feb 20, 2025 | Buy | +10,000 | $10.09 | $100.90K | 45,749 |
| David D. O'Toole CFO | Feb 20, 2025 | Buy | +1,000 | $9.90 | $9.90K | 25,734 |
| David D. O'Toole CFO | Feb 19, 2025 | Buy | +1,000 | $10.25 | $10.25K | 24,734 |
| Lou Panaccio Director | Jan 21, 2025 | Award | +10,022 | – | – | 56,428 |
| Jan Stern Reed Director | Jan 21, 2025 | Award | +10,022 | – | – | 51,011 |
| Suzanne Crowe Director | Jan 21, 2025 | Award | +10,022 | – | – | 46,934 |
| Robert McNamara Director | Jan 21, 2025 | Award | +10,022 | – | – | 66,771 |
| Cary Guy Vance Director | Jan 21, 2025 | Award | +10,022 | – | – | 35,771 |
| Jeremy Curnock Cook Director | Jan 21, 2025 | Award | +10,022 | – | – | 39,836 |
| Suzanne Crowe Director | Dec 9, 2024 | Buy | +486 | $13.15 | $6.39K | 36,912 |
| David D. O'Toole CFO | Dec 5, 2024 | Buy | +500 | $12.40 | $6.20K | 23,734 |
| David D. O'Toole CFO | Dec 5, 2024 | Buy | +475 | $12.53 | $5.95K | 23,234 |
| David D. O'Toole CFO | Nov 29, 2024 | Award | +785 | $7.83 | $6.15K | 22,759 |
| Robert McNamara Director | Aug 19, 2024 | Award | +10,000 | $9.00 | $90.00K | 35,749 |
| Cary Guy Vance Director | Jun 5, 2024 | Award | +9,200 | – | – | 25,749 |
| Lou Panaccio Director | Jun 5, 2024 | Award | +9,200 | – | – | 46,406 |
| Robert McNamara Director | Jun 5, 2024 | Award | +9,200 | – | – | 25,749 |
| Jeremy Curnock Cook Director | Jun 5, 2024 | Award | +9,200 | – | – | 29,814 |
| Jan Stern Reed Director | Jun 5, 2024 | Award | +9,200 | – | – | 40,989 |
| Suzanne Crowe Director | Jun 5, 2024 | Award | +9,200 | – | – | 36,426 |
| Donna Shiroma General Counsel | May 31, 2024 | Award | +2,225 | $8.17 | $18.18K | 45,951 |
| David D. O'Toole CFO | May 31, 2024 | Award | +2,240 | $8.17 | $18.30K | 21,974 |
| David D. O'Toole CFO | May 30, 2024 | Buy | +500 | $8.60 | $4.30K | 19,734 |
| David D. O'Toole CFO | May 30, 2024 | Buy | +500 | $9.20 | $4.60K | 19,234 |
| David D. O'Toole CFO | Feb 28, 2024 | Buy | +250 | $17.43 | $4.36K | 18,734 |
| David D. O'Toole CFO | Feb 28, 2024 | Buy | +1,000 | $17.38 | $17.38K | 18,484 |
| James Corbett CEO, Director | Dec 26, 2023 | Sale | −1,445 | $13.29 | $19.20K | 11,580 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AVITA Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 23,689 shares on Aug 20, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Liberto Erin Officer | Jun 8, 2023 | 122,531 | $2.08M | Jun 8, 2023 | STOCK OPTION EXERCISE |
See a number that looks wrong?